With the sequencing of the entire human genome coming closer by the day, the implications resulting from the exploitation of this information are becoming clearer. Intellectual property claims play an important role in the race between private and public sequencing efforts. While pharmaceutical companies are eager to use the generated knowledge to optimize drug development strategies, these will most likely neglect the intrests of developing countries.